Stroke is predominantly observed among the geriatric population and is globally considered as a major cause of death. The rise in adoption of unhealthy lifestyle patterns, alcohol and smoking addiction has collectively contributed to the rise in prevalence of stroke.
An immunoassay is a bioanalytical method used to detect or measure specific proteins or other substances through their properties as antigens or antibodies. A radioimmunoassay (RIA) is an immunoassay that uses an antigen labeled with a radioisotope and measure the subsequent radioactivity of the antibody component in order to detect the antigen-antibody complex. RIA is gaining noteworthy significance in medical diagnostics owing to its high precision, accuracy, specificity of results, and sensitivity.
Topical oxygen therapy market is anticipated to grow at a CAGR of 3.5% during the forecast period from 2019 to 2021. Factors driving this market include growing incidence of chronic wounds, increasing patient pool of diabetics, and high incidence of wound site infections. Some of the major trends responsible for market growth are increased number of surgical procedures, and technological advancement in advanced wound care.
As per Cleveland Clinic, primary Raynaud’s phenomenon affects around 5% to 10% of the general population. This phenomenon is predominantly observed among the female population aged 15 to 30 years.
Aptamers are chemically synthesized peptides or oligonucleotide molecules that bind to a specific target nucleic acid, protein, or lipid. Aptamers are used in various fields such as drug delivery, diagnostics, and therapeutics.
Cell isolation & separation is the process of separating individual living cells from another within a biological sample such as blood or tissue. Cell isolation & separation techniques comprise centrifugation, FACS (fluorescence-activated cell sorting), BACS (buoyancy-activated cell sorting), MACS (magnetic-activated cell sorting), and microfluidics or filtration.
Chiral column chromatography is a type of column chromatography wherein the stationary phase comprises a single enantiomer of a chiral compound instead of being achiral. Chiral separation of racemic drugs has rising importance in biotechnology & pharmaceutical industries in order to yield optimal therapeutic effect. Increasing significance of chromatography tests for drug approvals and technological advances in chromatography columns is expected to majorly drive the market growth during the forecast period.
The vasculitis treatment market expected to reach US$ 744.12 Mn by 2033 from US$ 407.8 Mn in 2021 and projected to exhibit a steady compound annual growth rate (CAGR) of 5.7% during the forecast period from 2025 to 2033.
Anti-counterfeit packaging technologies market is expected to reach US$ 522.0 Bn by 2033 with 12% CAGR during the forecast period from 2025 to 2033. In 2020, North America led the anti-counterfeit packaging technologies market. The Asia Pacific is estimated to be the fastest-growing region between 2025 and 2033.
Despite being a preventable and treatable condition, postpartum hemorrhage (PPH) the leading direct cause of maternal deaths worldwide. However, women in low respurce stings may not have desired access to appropriate care. This condition causes approximately 25% of the total maternal deaths. PPH is defined as excessive vaginal bleeding and occurs in over 10% of the total births and is linked with 1% case fatality rate. Active management of third stage labor can prevent up to 60% PPH cases, it still has devastating effect in low-income countries.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.